Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IMM2510,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Instil Bio Announces Clinical Progress for IMM2510/SYN-2510 in China
Details : IMM2510/SYN-2510 is a PD-L1xVEGF bispecific antibody, being investigated in combination with chemotherapy in patients with advanced non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : IMM2510,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMM2510
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : ImmuneOnco
Deal Size : $2,050.0 million
Deal Type : Licensing Agreement
Instil Bio and ImmuneOnco Announce License Agreement for IMM2510 and IMM27M Antibodies
Details : Instil is the in-licensing agreement with ImmuneOnc for ex-China development and commercial rights of ImmueOnco’s PD-L1xVEGF bispecific antibody, IMM2510 for the treating advanced solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
August 01, 2024
Lead Product(s) : IMM2510
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : ImmuneOnco
Deal Size : $2,050.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ITIL-306 is an autologous TIL cell therapy engineered with CoStAR molecule (activated by folate receptor alpha), which enhances the cytokine release, cytolytic activity, and proliferation of TILs in the tumor microenvironment.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 09, 2023
Lead Product(s) : ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. ITIL-168 is manufactured with Instil’s proprietary, which has been designed to capture and preserve the maximum diversity of each patient’s TIL...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 31, 2022
Details : ITIL-306 is an autologous TIL cell therapy engineered with a novel and proprietary CoStAR molecule that is activated by folate receptor alpha (FRα) to provide robust costimulatory signals within the tumor microenvironment.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 18, 2022
ITIL-306 in Advanced Solid Tumors
Details : ITIL-306 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Ovarian Epithelial.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ITIL-306 is an autologous TIL cell therapy engineered with a novel and proprietary Costimulatory Antigen Receptor (CoStAR) that is activated by folate receptor alpha (FRα) to provide robust costimulatory signals.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ITIL-168 in Advanced Solid Tumors
Details : ITIL-168 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 26, 2022
Details : ITIL-168 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 20, 2021
Details : ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs used in patients with checkpoint inhibitor-refractory advanced cutaneous melanoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 16, 2021